Cedar Point Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$404K Buy
337
+62
+23% +$63.3K 0.23% 53
2026
Q1
$253K Buy
275
+35
+15% +$35.5K 0.16% 65
2025
Q4
$258K Buy
+240
New +$229K 0.16% 62

Other funds holding LLY

Cedar Point Capital Partners's LLY Position: Q2 2026 in Review

Cedar Point Capital Partners increased its Eli Lilly (LLY) stake by 23% in Q2 2026, buying an estimated $63.3K and bringing the position to 337 shares worth $404K. The position accounts for 0.23% of the portfolio, ranked #53.

Cedar Point Capital Partners first reported a position in LLY in Q4 2025 and has held it in 3 quarters since. 4,634 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cedar Point Capital Partners held 337 shares of Eli Lilly worth $404K as of Q2 2026.
  • Cedar Point Capital Partners bought 62 Eli Lilly shares in Q2 2026, an estimated $63.3K.
  • Eli Lilly made up 0.23% of Cedar Point Capital Partners's portfolio in Q2 2026, its #53 holding.
  • Cedar Point Capital Partners first reported a position in Eli Lilly in Q4 2025 and has held it in 3 quarters since.
  • 4,634 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cedar Point Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.